<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04206332</url>
  </required_header>
  <id_info>
    <org_study_id>200017</org_study_id>
    <secondary_id>20-I-0017</secondary_id>
    <nct_id>NCT04206332</nct_id>
  </id_info>
  <brief_title>Trial to Evaluate CIS43LS in Healthy Adults</brief_title>
  <official_title>VRC 612: A Phase 1, Dose Escalation, Open-Label Clinical Trial With Experimental Controlled Human Malaria Infections (CHMI) to Evaluate Safety and Protective Efficacy of an Anti-Malaria Human Monoclonal Antibody, VRC-MALMAB0100-00-AB (CIS43LS), in Healthy, Malaria-Naive Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background:&#xD;
&#xD;
      People get malaria when they are bitten by an infected mosquito. Malaria can be serious and&#xD;
      sometimes deadly. Although there are medicines to treat malaria, there is no vaccine that&#xD;
      fully prevents infection. Researchers want to test if an experimental drug can help.&#xD;
&#xD;
      Objective:&#xD;
&#xD;
      To test a drug called CIS43LS that could prevent malaria infection.&#xD;
&#xD;
      Eligibility:&#xD;
&#xD;
      Healthy people ages 18-50 who have never been infected with malaria&#xD;
&#xD;
      Design:&#xD;
&#xD;
      Participants will be screened with a physical exam, blood tests, and medical history.&#xD;
&#xD;
      Some participants will get pregnancy tests.&#xD;
&#xD;
      Most participants will get CIS43LS. They will get the drug infused into a vein in their arm&#xD;
      or injected into the fat under the skin. They will be monitored for side effects for up to 4&#xD;
      hours after they get the drug.&#xD;
&#xD;
      Participants will be given a thermometer to check their temperature every day for 7 days.&#xD;
      They will also be given a device to measure any redness, swelling, or bruising at the&#xD;
      injection site.&#xD;
&#xD;
      Participants will have up to 12 follow-up visits. These will include blood tests.&#xD;
&#xD;
      Most participants will take part in a Controlled Human Malaria Challenge (CHMI). During the&#xD;
      CHMI, mosquitoes carrying the malaria parasite will bite participants in a controlled&#xD;
      setting. The participants will then have clinic visits every day for up to 12 days starting 7&#xD;
      days after the CHMI. They will be treated right away with antimalarial medication if the test&#xD;
      shows positive for malaria. If participants continue to test negative for malaria, they will&#xD;
      have 2 more visits over the next 6 days for blood tests. Then 28 days after the CHMI they&#xD;
      will get treated with antimalarial medication for 3 days. The study will last 2-6 months&#xD;
      depending on participants study group....&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 1, open-label, dose escalation study to evaluate the dose, safety,&#xD;
      tolerability and protective efficacy of an anti-malaria human monoclonal antibody,&#xD;
      VRC-MALMAB0100-00-AB (CIS43LS). The primary hypothesis is to evaluate the safety and&#xD;
      tolerability of CIS43LS when administered by either intravenous (IV) or subcutaneous (SC)&#xD;
      routes. The secondary objectives are that CIS43LS will be detectable in human sera with a&#xD;
      definable half-life and will confer protection following a controlled human malaria infection&#xD;
      (CHMI).&#xD;
&#xD;
      Part A: Part A evaluated the doses and routes as shown below in the Study Schema table in an&#xD;
      open-label, dose escalation design.&#xD;
&#xD;
      Part B: Part B evaluated CIS43LS doses and routes prior to CHMI in Part A veteran subjects&#xD;
      and new Part B enrollees.&#xD;
&#xD;
      Part C: Part C will evaluate CIS43LS doses and routes needed to reach a threshold of&#xD;
      protection by assessing serum concentration prior to CHMI in a dose down design.&#xD;
&#xD;
      Enrollment of up to 100 healthy subjects, 18-50 years of age, who are malaria-naive is&#xD;
      permitted. All subjects who receive CIS43LS will be followed for 24 weeks after product&#xD;
      administration. Control subjects will be followed through 8 weeks after CHMI.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 7, 2020</start_date>
  <completion_date type="Anticipated">April 5, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 5, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the safety and tolerability of CIS43LS</measure>
    <time_frame>Through 24 weeks after product administration</time_frame>
    <description>1 mg/kg IV of CIS43LS will be administered to healthy, malaria-naive adults.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To evaluate the safety and tolerability of CIS43LS</measure>
    <time_frame>Through 24 weeks after product administration</time_frame>
    <description>10 mg/kg SC of CIS43LS will be administered to healthy, malaria-naive adults.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To evaluate the safety and tolerability of CIS43LS</measure>
    <time_frame>Through 24 weeks after product administration</time_frame>
    <description>5 mg/kg IV of CIS43LS will be administered to healthy, malaria-naive adults.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To evaluate the safety and tolerability of CIS43LS</measure>
    <time_frame>Through 24 weeks after product administration</time_frame>
    <description>5 mg/kg SC of CIS43LS will be administered to healthy, malaria-naive adults.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To evaluate the safety and tolerability of CIS43LS</measure>
    <time_frame>Through 24 weeks after product administration</time_frame>
    <description>20 mg/kg IV of CIS43LS will be administered to healthy, malaria-naive adults.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To evaluate the safety and tolerability of CIS43LS</measure>
    <time_frame>Through 24 weeks after product administration</time_frame>
    <description>10 mg/kg IV of CIS43LS will be administered to healthy, malaria-naive adults.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To evaluate the safety and tolerability of CIS43LS</measure>
    <time_frame>Through 24 weeks after product administration</time_frame>
    <description>40 mg/kg IV of CIS43LS will be administered to healthy, malaria-naive adults.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine if CIS43LS confers protection</measure>
    <time_frame>Following CHMI</time_frame>
    <description>To determine if the administration of CIS43LS confers protection against plasmodium falciparum following CHMI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the pharmacokinetics of CIS43LS at each dose level</measure>
    <time_frame>Throughout the study</time_frame>
    <description>The pharmocokinetics of CIS43LS administered at each dose level will be evaluated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To estimate the lowest dose of CIS43LS administered IV and SC</measure>
    <time_frame>Following CHMI</time_frame>
    <description>To estimate the lowest dose that confers protection against plasmodium falciparum following CHMI.</description>
  </secondary_outcome>
  <number_of_arms>17</number_of_arms>
  <enrollment type="Anticipated">73</enrollment>
  <condition>Malaria</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5 mg/kg IV</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 10</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Control</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 11</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 mg/kg IV</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 12</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5 mg/kg IV</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 13</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5 mg/kg SC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 14</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 mg/kg IV</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 15</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 mg/kg SC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 16</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Control</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5 mg/kg SC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20 mg/kg IV</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4a</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>40 mg/kg IV</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4b</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>40 mg/kg IV</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Control</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5 mg/kg SC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 7</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20 mg/kg IV</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 8</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No additional study product</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 9</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>40 mg/kg IV</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VRC-MALMAB0100-00-AB</intervention_name>
    <description>VRC-MALMAB0100-00-AB is a monoclonal antibody that recognizes a unique and conserved region of the Plasmodium falciparum circumsporozoite protein. The monoclonal antibody was adapted resulting in an LS mutation found to increase product half-life in plasma.</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 11</arm_group_label>
    <arm_group_label>Group 12</arm_group_label>
    <arm_group_label>Group 13</arm_group_label>
    <arm_group_label>Group 14</arm_group_label>
    <arm_group_label>Group 15</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_label>Group 4a</arm_group_label>
    <arm_group_label>Group 4b</arm_group_label>
    <arm_group_label>Group 6</arm_group_label>
    <arm_group_label>Group 7</arm_group_label>
    <arm_group_label>Group 9</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>CHMI</intervention_name>
    <description>Negative control designed to test the infection ability of the CHMI.</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 11</arm_group_label>
    <arm_group_label>Group 12</arm_group_label>
    <arm_group_label>Group 13</arm_group_label>
    <arm_group_label>Group 14</arm_group_label>
    <arm_group_label>Group 15</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_label>Group 4a</arm_group_label>
    <arm_group_label>Group 4b</arm_group_label>
    <arm_group_label>Group 5</arm_group_label>
    <arm_group_label>Group 6</arm_group_label>
    <arm_group_label>Group 7</arm_group_label>
    <arm_group_label>Group 9</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:&#xD;
&#xD;
        A subject must meet all of the following criteria to be included:&#xD;
&#xD;
          1. Able and willing to complete the informed consent process&#xD;
&#xD;
          2. Able to provide proof of identity to the satisfaction of the study clinician&#xD;
             completing the enrollment process&#xD;
&#xD;
          3. Available for clinical follow-up through the last study visit&#xD;
&#xD;
          4. 18 to 50 years of age&#xD;
&#xD;
          5. In good general health without clinically significant medical history&#xD;
&#xD;
          6. Physical examination without clinically significant findings within the 56 days prior&#xD;
             to enrollment&#xD;
&#xD;
          7. Weight &lt;= 115 kg (for all groups except Groups 5, 10, and 16) and &lt; 100 kg for Group&#xD;
             15&#xD;
&#xD;
          8. Adequate venous access if assigned to an IV group or adequate subcutaneous tissue if&#xD;
             assigned to an SC group&#xD;
&#xD;
          9. Willing to have blood samples collected, stored indefinitely, and used for research&#xD;
             purposes&#xD;
&#xD;
         10. Agrees to participate in a controlled human malaria infection (CHMI) and to comply&#xD;
             with post-CHMI follow-up requirements (except Group 4B)&#xD;
&#xD;
         11. Agrees to refrain from blood donation to blood banks for 3 years following&#xD;
             participation in CHMI (except Group 4B)&#xD;
&#xD;
         12. Agrees not to travel to a malaria endemic region during the entire course of study&#xD;
             participation&#xD;
&#xD;
             Laboratory Criteria within 56 days prior to enrollment:&#xD;
&#xD;
         13. WBC 2,500-12,000/mm^3&#xD;
&#xD;
         14. WBC differential either within institutional normal range or accompanied by the&#xD;
             Principal Investigator (PI) or designee approval&#xD;
&#xD;
         15. Platelets = 125,000 - 400,000/mm^3&#xD;
&#xD;
         16. Hemoglobin within institutional normal range or accompanied by the PI or designee&#xD;
             approval&#xD;
&#xD;
         17. Creatinine &lt;= 1.1 x upper limit of normal (ULN)&#xD;
&#xD;
         18. Alanine aminotransferase (ALT) &lt;= 1.25 x ULN&#xD;
&#xD;
         19. Negative for HIV infection by an FDA approved method of detection&#xD;
&#xD;
             Laboratory Criteria documented any time prior to enrollment:&#xD;
&#xD;
         20. Negative sickle cell screening test&#xD;
&#xD;
         21. Negative troponin test (except Group 4B)&#xD;
&#xD;
         22. Electrocardiogram (ECG) without clinically significant abnormalities (examples may&#xD;
             include: pathologic Q waves, significant ST-T wave changes, left ventricular&#xD;
             hypertrophy, any non-sinus rhythm excluding isolated premature atrial contractions,&#xD;
             right or left bundle branch block, advanced A-V heart block). ECG abnormalities&#xD;
             determined by a cardiologist to be clinically insignificant as related to study&#xD;
             participation do not preclude study enrollment (except Group 4B)&#xD;
&#xD;
         23. No evidence of increased cardiovascular disease risk; defined as &gt;10% five-year risk&#xD;
             by the non-laboratory method (except Group 4B)&#xD;
&#xD;
             Criteria Specific to Women:&#xD;
&#xD;
         24. Postmenopausal for at least 1 year, post-hysterectomy or bilateral oophorectomy, or if&#xD;
             of childbearing potential:&#xD;
&#xD;
               1. Negative beta-human chorionic gonadotropin (beta-HCG) pregnancy test (urine or&#xD;
                  serum) on day of enrollment, and prior to product administration and CHMI, and&#xD;
&#xD;
               2. Agrees to use an effective means of birth control through the duration of study&#xD;
                  participation&#xD;
&#xD;
        EXCLUSION CRITERIA:&#xD;
&#xD;
        A subject will be excluded if one or more of the following conditions apply:&#xD;
&#xD;
          1. Woman who is breast-feeding or planning to become pregnant during study participation&#xD;
&#xD;
          2. Previous receipt of a malaria vaccine&#xD;
&#xD;
          3. History of malaria infection&#xD;
&#xD;
          4. History of severe infection with severe acute respiratory syndrome coronavirus 2&#xD;
             (SARS-CoV-2) defined per FDA guidance&#xD;
&#xD;
          5. Active SARS-CoV-2 infection&#xD;
&#xD;
          6. Any history of a severe allergic reaction with generalized urticaria, angioedema or&#xD;
             anaphylaxis prior to enrollment that has a reasonable risk of recurrence during the&#xD;
             study&#xD;
&#xD;
          7. Hypertension that is not well controlled&#xD;
&#xD;
          8. Receipt of any investigational study product within 28 days prior to enrollment (note:&#xD;
             Emergency Use Authorization COVID-19 vaccine is not exclusionary)&#xD;
&#xD;
          9. Receipt of any live attenuated vaccines within 28 days prior to enrollment&#xD;
&#xD;
         10. Bleeding disorder diagnosed by a doctor (e.g. factor deficiency, coagulopathy, or&#xD;
             platelet disorder requiring special precautions) or significant bruising or bleeding&#xD;
             difficulties with intramuscular injections or blood draws&#xD;
&#xD;
         11. History of a splenectomy, sickle cell disease or sickle cell trait&#xD;
&#xD;
         12. History of skeeter syndrome or anaphylactic response to mosquito-bites (except Group&#xD;
             4B)&#xD;
&#xD;
         13. Known intolerance to chloroquine phosphate, atovaquone or proguanil (except Group 4B)&#xD;
&#xD;
         14. Use or planned use of any drug, including antibiotics, with antimalarial activity&#xD;
             within 4 weeks prior to CHMI&#xD;
&#xD;
         15. History of psoriasis or porphyria, which may be exacerbated after treatment with&#xD;
             chloroquine (except Group 4B)&#xD;
&#xD;
         16. Anticipated use of medications known to cause drug reactions with chloroquine or&#xD;
             atovaquone-proguanil (Malarone) such as cimetidine, metoclopramide, antacids, and&#xD;
             kaolin (except Group 4B)&#xD;
&#xD;
         17. Any other chronic or clinically significant medical condition that in the opinion of&#xD;
             the investigator would jeopardize the safety or rights of the volunteer, including but&#xD;
             not limited to: diabetes mellitus type I, chronic hepatitis; OR clinically significant&#xD;
             forms of: drug or alcohol abuse, asthma, autoimmune disease, psychiatric disorders,&#xD;
             heart disease, or cancer&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martin R Gaudinski, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institute of Allergy and Infectious Diseases (NIAID)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>VRC Clinic</last_name>
    <phone>(301) 451-8715</phone>
    <email>vaccines@nih.gov</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Maryland Baltimore, Center for Vaccine Development</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201-1595</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristen Lyke</last_name>
      <phone>410-706-0462</phone>
      <email>klyke@som.umaryland.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>VRC Clinic</last_name>
      <phone>301-451-8715</phone>
      <email>vaccines@nih.gov</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://clinicalstudies.info.nih.gov/cgi/detail.cgi?A_2020-I-0017.html</url>
    <description>NIH Clinical Center Detailed Web Page</description>
  </link>
  <reference>
    <citation>Gaudinski MR, Coates EE, Novik L, Widge A, Houser KV, Burch E, Holman LA, Gordon IJ, Chen GL, Carter C, Nason M, Sitar S, Yamshchikov G, Berkowitz N, Andrews C, Vazquez S, Laurencot C, Misasi J, Arnold F, Carlton K, Lawlor H, Gall J, Bailer RT, McDermott A, Capparelli E, Koup RA, Mascola JR, Graham BS, Sullivan NJ, Ledgerwood JE; VRC 608 Study team. Safety, tolerability, pharmacokinetics, and immunogenicity of the therapeutic monoclonal antibody mAb114 targeting Ebola virus glycoprotein (VRC 608): an open-label phase 1 study. Lancet. 2019 Mar 2;393(10174):889-898. doi: 10.1016/S0140-6736(19)30036-4. Epub 2019 Jan 24. Erratum in: Lancet. 2020 May 30;395(10238):1694.</citation>
    <PMID>30686586</PMID>
  </reference>
  <reference>
    <citation>Ishizuka AS, Lyke KE, DeZure A, Berry AA, Richie TL, Mendoza FH, Enama ME, Gordon IJ, Chang LJ, Sarwar UN, Zephir KL, Holman LA, James ER, Billingsley PF, Gunasekera A, Chakravarty S, Manoj A, Li M, Ruben AJ, Li T, Eappen AG, Stafford RE, K C N, Murshedkar T, DeCederfelt H, Plummer SH, Hendel CS, Novik L, Costner PJ, Saunders JG, Laurens MB, Plowe CV, Flynn B, Whalen WR, Todd JP, Noor J, Rao S, Sierra-Davidson K, Lynn GM, Epstein JE, Kemp MA, Fahle GA, Mikolajczak SA, Fishbaugher M, Sack BK, Kappe SH, Davidson SA, Garver LS, Björkström NK, Nason MC, Graham BS, Roederer M, Sim BK, Hoffman SL, Ledgerwood JE, Seder RA. Protection against malaria at 1 year and immune correlates following PfSPZ vaccination. Nat Med. 2016 Jun;22(6):614-23. doi: 10.1038/nm.4110. Epub 2016 May 9. Erratum in: Nat Med. 2016 Jun 7;22(6):692.</citation>
    <PMID>27158907</PMID>
  </reference>
  <reference>
    <citation>Seder RA, Chang LJ, Enama ME, Zephir KL, Sarwar UN, Gordon IJ, Holman LA, James ER, Billingsley PF, Gunasekera A, Richman A, Chakravarty S, Manoj A, Velmurugan S, Li M, Ruben AJ, Li T, Eappen AG, Stafford RE, Plummer SH, Hendel CS, Novik L, Costner PJ, Mendoza FH, Saunders JG, Nason MC, Richardson JH, Murphy J, Davidson SA, Richie TL, Sedegah M, Sutamihardja A, Fahle GA, Lyke KE, Laurens MB, Roederer M, Tewari K, Epstein JE, Sim BK, Ledgerwood JE, Graham BS, Hoffman SL; VRC 312 Study Team. Protection against malaria by intravenous immunization with a nonreplicating sporozoite vaccine. Science. 2013 Sep 20;341(6152):1359-65. doi: 10.1126/science.1241800. Epub 2013 Aug 8.</citation>
    <PMID>23929949</PMID>
  </reference>
  <verification_date>October 29, 2021</verification_date>
  <study_first_submitted>December 19, 2019</study_first_submitted>
  <study_first_submitted_qc>December 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 20, 2019</study_first_posted>
  <last_update_submitted>October 30, 2021</last_update_submitted>
  <last_update_submitted_qc>October 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prevention and Control</keyword>
  <keyword>Mosquito</keyword>
  <keyword>Malaria Challenge</keyword>
  <keyword>Parasitemia</keyword>
  <keyword>Passive Immunization</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malaria</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

